These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 20961248)

  • 1. Ranibizumab therapy for neovascular age-related macular degeneration.
    Folk JC; Stone EM
    N Engl J Med; 2010 Oct; 363(17):1648-55. PubMed ID: 20961248
    [No Abstract]   [Full Text] [Related]  

  • 2. Ranibizumab for age-related macular degeneration.
    Cheng JW; Wei RL
    N Engl J Med; 2011 Feb; 364(6):582. PubMed ID: 21306263
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions.
    Messori A; Fadda V; Trippoli S
    Am J Ophthalmol; 2010 May; 149(5):867; author reply 867. PubMed ID: 20399931
    [No Abstract]   [Full Text] [Related]  

  • 4. Ranibizumab for age-related macular degeneration.
    Trempe C
    N Engl J Med; 2011 Feb; 364(6):581-2. PubMed ID: 21306264
    [No Abstract]   [Full Text] [Related]  

  • 5. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
    Donahue SP; Recchia F; Sternberg P
    Am J Ophthalmol; 2010 Aug; 150(2):287; author reply 287. PubMed ID: 20670740
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.
    Holz FG; Amoaku W; Donate J; Guymer RH; Kellner U; Schlingemann RO; Weichselberger A; Staurenghi G;
    Ophthalmology; 2011 Apr; 118(4):663-71. PubMed ID: 21459217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy.
    Arias L; Caminal JM; Badia MB; Rubio MJ; Catala J; Pujol O
    Retina; 2010; 30(10):1601-8. PubMed ID: 21060271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
    Subramanian ML; Ness S; Abedi G; Ahmed E; Daly M; Feinberg E; Bhatia S; Patel P; Nguyen M; Houranieh A
    Am J Ophthalmol; 2009 Dec; 148(6):875-82.e1. PubMed ID: 19800611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials.
    Mitchell P; Korobelnik JF; Lanzetta P; Holz FG; Prünte C; Schmidt-Erfurth U; Tano Y; Wolf S
    Br J Ophthalmol; 2010 Jan; 94(1):2-13. PubMed ID: 19443462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
    de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
    Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of repeated intravitreal bevacizumab injections on the inner retinal function in neovascular age-related macular degeneration.
    Kim HD; Kim SH; Cho IH; Moon CH; Ohn YH; Park TK
    Acta Ophthalmol; 2013 Mar; 91(2):e154-6. PubMed ID: 22989051
    [No Abstract]   [Full Text] [Related]  

  • 13. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Schachat AP
    Am J Ophthalmol; 2013 Jul; 156(1):1-2.e1. PubMed ID: 23791369
    [No Abstract]   [Full Text] [Related]  

  • 15. Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.
    Klein RM; Klein RB
    Retina; 2007; 27(9):1163-5. PubMed ID: 18046218
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab.
    Smith AG; Kaiser PK
    Dev Ophthalmol; 2016; 55():246-51. PubMed ID: 26501149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experience of Lucentis use in patients with wet age-related macular degeneration].
    Dolgova IG; Malishevskaia TN; Rybina IM
    Vestn Oftalmol; 2012; 128(5):26-31. PubMed ID: 23210344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
    Cho HJ; Kim CG; Yoo SJ; Cho SW; Lee DW; Kim JW; Lee JH
    Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy.
    Tabandeh H; Chaudhry NA; Boyer DS; Kon-Jara VA; Flynn HW
    J Cataract Refract Surg; 2012 Apr; 38(4):677-82. PubMed ID: 22284725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Third nerve palsy following intravitreal anti-VEGF therapy for bilateral neovascular age-related macular degeneration.
    Micieli JA; Santiago P; Brent MH
    Acta Ophthalmol; 2011 Feb; 89(1):e99-100. PubMed ID: 19925526
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.